

**To:** Strynar, Mark[Strynar.Mark@epa.gov]; McCord, James[mccord.james@epa.gov]  
**Cc:** Jane Hoppin[jahoppin@ncsu.edu]; Detlef R. U. Knappe[knappe@ncsu.edu]  
**From:** Nadine Kotlarz[nkotlar@ncsu.edu]  
**Sent:** Mon 4/20/2020 7:49:40 PM (UTC)  
**Subject:** MS/MS fragmentation details for blood manuscript  
[PFAS blood EHP text fig suppl.pdf](#)

Hey James and Mark,  
I am working through the EHP reviewers' comments on our blood paper (submitted ms is attached).

The editor refers to the following line in our manuscript

“Targeted MS/MS on 10 randomly selected serum samples revealed diagnostic fragments of Hydro-EVE (i.e., 184.9840 corresponding to C3F7O-) as well as 6:2 FTS (i.e., 80.9652 corresponding to HSO3-) at the same retention time, indicating that both Hydro-EVE and 6:2 FTS were present in at least a subset of serum samples.”

They ask us to "Please add a brief description of this analysis to the methods section, including information about the source of the randomly selected serum samples."

Here's the response I drafted... but need your help with.

**Ex. 5 Deliberative Process (DP)**

How might you word this differently, and what else would you add?

Thanks for your help,  
Nadine